English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, August 4, 2022
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial
Tuesday, July 26, 2022
エーザイ、レカネマブのARIA-E発現、皮下注射製剤に関する発表を含むアルツハイマー病/認知症領域の開発品に関する最新データをアルツハイマー病協会国際会議 2022にて発表
エーザイ、社会的責任投資指数「FTSE4Good Index Series」の構成銘柄に21年連続で選定
Eisai Listed for 21st Consecutive Year in FTSE4Good Index Series
Tuesday, March 12, 2019
エーザイ、米国FDAが不眠障害治療薬「レンボレキサント」の新薬承認申請を受理
Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia
Thursday, March 7, 2019
エーザイ、不眠障害治療薬「レンボレキサント」について日本において新薬承認申請書を提出
Eisai's Marketing Authorization Application for Potential Insomnia Disorder Treatment Lemborexant Submitted in Japan
Wednesday, February 27, 2019
エーザイ、国際NGO「難民を助ける会」とスーダンでの活動を支援する契約を締結
Eisai Enters Into Agreement to Support International Ngo Association for Aid and Relief, Japan's Activities in Sudan

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575